Coverage Without Mortality Evidence: How Medicare's 2026 MCED Pivot Restructures Cancer Screening Ahead of the Data

Beneath the headline launch of multi-cancer blood tests, the Sewell Act enacted February 2026 has authorised Medicare coverage of MCED screening from 2028 even as the landmark NHS-Galleri trial missed its primary endpoint — restructuring cancer-screening economics, payer evidence standards, and primary-care workflows on a 2027-2030 inflection.

The consensus narrative on multi-cancer early detection is technology triumph: a single blood test that screens for 50+ cancers, with the promise of moving from late-stage to early-stage diagnosis. True as far as it goes. Beneath it sits a more consequential structural shift: the United States has authorised Medicare coverage of MCED testing from 2028 without FDA approval of any such test and without evidence that population screening reduces cancer mortality — and it did so weeks before the landmark NHS-Galleri trial missed its primary endpoint. The strategic question for healthcare boards, payers and policymakers is no longer whether MCED is coming; it is what happens when coverage decisions outrun the evidence base in a way that becomes the operating template for AI-discovery diagnostics, polygenic risk scores and other next-generation screening technologies.

Signal Identification

This is a regulatory-evidence inflection: a major payer commitment has been enacted ahead of the FDA approval, ahead of the mortality endpoint data, and ahead of the cost-effectiveness consensus. The signal is the policy-evidence gap itself, not MCED technology — the gap creates a template for coverage-led adoption in next-generation screening and a new political-economy logic for payer decision-making.

Time horizon: 2-5 years (Sewell Act enacted 03/02/2026; FDA Galleri PMA decision expected 2026-2027; Medicare coverage trigger 2028; mortality endpoint data 2028-2030) Plausibility band: High Geographic / Jurisdictional Scope: Primary: United States (Medicare, CMS, FDA, USPSTF). Spillover: NHS England (NHS-Galleri commissioning decision pending ASCO 2026 data); Germany G-BA, France HAS, Australia MSAC; private US payers (UnitedHealth, Anthem, Aetna); employer health-benefit plans. Sectors exposed: Diagnostics manufacturers (Grail, Exact Sciences, Guardant, Natera, Burning Rock); commercial labs (LabCorp, Quest); oncology providers and academic medical centres; primary-care physician networks; pharmacy benefit managers; CMS, USPSTF, NICE, IQWiG, MSAC; pharma companion-diagnostic strategies; cancer-screening advocacy organisations; AI-discovery diagnostics platforms.

What's Changing

Medicare coverage authority has been formally created for blood-based MCED testing ahead of FDA approval. The Nancy Gardner Sewell Medicare MCED Screening Coverage Act was signed into law on 3 February 2026 (04/02/2026), as part of the FY2026 appropriations package and following a 341-88 bipartisan House vote; it was the most co-sponsored bill in the 119th Congress (339 House, 68 Senate sponsors). The Act creates CMS authority to cover MCED tests once FDA-approved with demonstrated clinical benefit, with coverage trigger from 2028. The statutory pathway is now in place; the FDA approval and mortality endpoint data are not.

The landmark Phase 3 evidence base for the leading test missed its primary endpoint. Fierce Biotech reported (20/02/2026) that the NHS-Galleri trial in 142,000 NHS participants aged 50-77 — designed over three years to inform a UK commissioning decision — did not show statistically significant Stage III-IV cancer reduction; Grail's share price fell sharply, with The Cancer Letter (27/02/2026) noting Grail will extend follow-up 6-12 months and present detailed data at ASCO 2026. A favourable but non-significant trend was observed in 12 pre-specified deadly cancers; Stage IV diagnoses declined >20% in years two and three.

FDA regulatory submission is now in for the leading test, but approval timing is uncertain. Grail submitted the final module of its Premarket Approval application for Galleri on 29 January 2026 (29/01/2026), positioning Galleri to potentially be the first FDA-approved MCED test if PMA review succeeds; the FDA has not previously approved a multi-cancer screening test, and the review will draw on the mixed Phase 3 evidence base. The Sewell Act coverage trigger explicitly requires FDA approval plus demonstrated clinical benefit — both potential bottlenecks now in play.

The peer-reviewed literature is explicitly framing this as a policy-evidence misalignment. A Nature Reviews Clinical Oncology piece by Tibau and Kesselheim (22/04/2026) directly observes that Sewell Act coverage was enacted "given the lack of FDA approval of any MCED test or evidence that population screening with such tests reduces cancer-related or all-cause mortality", and warns of payer and policymaker implications of coverage authority running ahead of the evidence base. The methodological design issues are also formally on the table in a Journal of the National Cancer Institute analysis (15/03/2026) of NHS-Galleri trial-design unique issues.

Disruption Pathway

The pathway runs in three overlapping stages. Stage one (2026-2027): FDA Galleri PMA decision sets the template for MCED regulatory review and informs follow-on submissions from Exact Sciences, Guardant and Natera; NHS-Galleri extended follow-up and ASCO 2026 readout determine NHS commissioning posture. Stage two (2027-2028): CMS issues coverage determinations and pricing methodology under Sewell; commercial payers follow Medicare or push back; USPSTF assessment lands and shapes primary-care guideline integration; AJMC's coverage analysis (04/02/2026) frames the coverage-without-mortality challenge. Stage three (2028-2030): mortality endpoint data matures; coverage decisions consolidate or face pushback from ICER cost-effectiveness analyses; the precedent shapes payer policy on AI-discovery diagnostics and polygenic risk scores.

Stresses concentrate at three pressure points: primary-care workflows that must integrate complex MCED interpretation, signal-of-origin follow-up imaging and patient counselling without robust mortality data; guideline bodies (USPSTF, NICE, NCCN) reconciling evidence thresholds developed for single-cancer screens with multi-cancer pan-screening; and payer cost-effectiveness frameworks, where Galleri's ~$949 list price for annual screening across Medicare's 65+ population creates a coverage-cost step-change unprecedented in single-cancer screening history. Two structural adaptations follow: operational (clinical-pathway redesign for positive results and signal-of-origin discordance) and financial (risk-shared payer arrangements and competitor MCED pricing anchored to Galleri's PMA outcome).

Why This Matters

For diagnostic-manufacturer boards, the Sewell Act creates an effective demand floor for MCED tests from 2028 once FDA-approval and clinical-benefit thresholds are met — but it also creates an asymmetric exit if mortality data fails to materialise. For payer and CMS boards, the question moves from "should we cover MCED?" to "on what cost-effectiveness and outcomes framework, given coverage authority outpacing the evidence base?". For provider networks and primary-care leaders, the operational integration of MCED into the cancer-screening pathway is now a 2027-2028 design problem, not a research-grade speculation. For pharma companion-diagnostic strategies and AI-discovery diagnostics platforms, the Sewell coverage precedent reshapes the regulatory-coverage strategy for the next generation of screening modalities.

Decision-action posture for this signal: Prepare — statutory coverage authority is in place, FDA decision and key trial data are imminent; scenario planning and operational architecture preparation is the correct posture this cycle for the named constituencies.

Counter-Argument

The strongest objection is that the Sewell Act is conditional, not unconditional — Medicare coverage only triggers once FDA-approval and demonstrated clinical benefit are achieved, and the NHS-Galleri primary-endpoint miss makes it less likely that the demonstrated-clinical-benefit threshold will be cleared on currently-available data. The Cancer Letter (27/02/2026) notes Grail itself has extended follow-up by 6-12 months and is reframing the favourable Stage IV trend rather than the missed primary endpoint as the headline result, signalling that even Grail recognises the primary evidence base needs reinforcement. CMS and USPSTF may simply decline to cover MCED in 2028 absent further mortality data; the statutory pathway becomes a permission slip that is not exercised. On this reading, the "coverage outrunning evidence" framing is rhetorical rather than operational, and current MCED economics remain anchored to private-pay and self-pay markets.

This is partly right but understates the political-economy momentum. The Sewell Act was the most co-sponsored bill in the 119th Congress; cancer-advocacy organisations and patient groups will press CMS hard on any cautious coverage determination; and competing MCED manufacturers will optimise their evidence packages to satisfy a coverage standard that is now statutorily defined. Even a conservative CMS coverage decision in 2028 sets a template — and the precedent itself reshapes how next-generation screening technologies are positioned for payer evidence packages.

Implications

The signal catalyses durable structural change in payer-evidence frameworks. The Sewell Act precedent — that coverage authority can be enacted ahead of FDA approval and mortality endpoints for population-level screening — will inform the regulatory-coverage strategy for AI-discovery diagnostics, polygenic risk scores, multi-omic screening, and next-generation companion diagnostics through the late 2020s. Grail and follow-on MCED manufacturers gain a privileged regulatory pathway; established cancer-screening manufacturers (mammography, colonoscopy, low-dose CT) face displacement risk in primary-care guideline integration; payers acquire an unfamiliar coverage-evidence framework that will be replicated to other diagnostic categories. Primary-care workflows, oncology referral patterns and academic-medical-centre cancer-screening volumes are the operational variables now in motion.

Early Indicators to Monitor

Disconfirming Signals

Strategic Questions

Keywords

Multi-cancer early detection; MCED; Galleri Grail; Nancy Gardner Sewell Act; Medicare coverage; NHS-Galleri trial; FDA PMA; cancer screening; USPSTF; CMS coverage; coverage-evidence gap; AI diagnostics

Bibliography

This Signal Scan is one component of a Shaping Tomorrow intelligence cycle on Health, Life Sciences & Care Systems. Every monitored topic also includes monthly Change Trackers that assess what is materially shifting in momentum, and a quarterly Decision Intelligence briefing that converts the cycle into board-level strategic implications. Cycles may also close with Action Triggers, an end-of-cycle synthesis that reads across the three formats and surfaces patterns no single deliverable carries on its own. Continuous intelligence on this topic is available as a Single-Topic or Multi-Topic programme.

Discuss a Tailored Programme